PFNLive
- Stocks Drift Mostly Higher; Pfizer Weighs on Dow
- Bristol Profit Drops Sharply, but Meets Wall Street Forecast
- Biogen Profit Beats Estimates on Tysabri Revenue Increase
- Stock Futures Add to Gains after Jobs Data
- AstraZeneca Hit by Generic Drugs and Crestor Shortfall
- Bayer Profit Barely Rises as Plastics Offset New Drugs
- Merck Scores 'Breakthrough' Status from FDA for Immunotherapy Against Melanoma
- Amgen Falls After Revenue Growth Misses Estimates
- P&G Forecasts Profit Below Street, Shares Drop
- GSK puts Lucozade and Ribena Drink Brands up for Sale
- WellPoint Beats Earnings Estimates on Low Medical Costs
- Eli Lilly Profit Beats Estimates on Lower Costs
- Stocks Little Changed as Investors Weigh Earnings
- Glaxo Profit Falls on Divestments as Approvals Awaited
- Thermo Fisher Profit Tops Street View as Life Deal Awaits
- Wall Street Set for Flat Open after Durable Goods Data
- Boehringer Anti-Clotting Pill Gains Blockbuster Status
- Novartis Profit Rises 7% on Lack of Generic Diovan
- Elan Sees Sales of Prized Tysabri Drug Rise Sharply
- Wall Street Rallies After Recovery from Twitter-Driven Drop
